2 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
Follow iptacopan: new trials by email Literature Review of iptacopan trials Research Report on iptacopan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V Iptacopan (part 1), Iptacopan (part 2), Placebo + standard of care - Lupus Nephritis | Phase 2 | Terminated | Novartis Pharmaceuticals | 81 | 2022-08-10 | 2026-10-15 |
| Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders Iptacopan - Immune Thrombocytopenia (ITP), Cold Agglutinin Disease (CAD) | Phase 2 | Terminated | Novartis Pharmaceuticals | 19 | 2021-12-21 | 2025-10-16 |
Anemia, Hemolytic, Autoimmune (1) · Lupus Erythematosus, Systemic (1) · Lupus Nephritis (1) · Proteinuria (1) · Purpura, Thrombocytopenic, Idiopathic (1)
Germany (2) · Spain (2) · United Kingdom (2) · United States (2) · Argentina (1) · Brazil (1) · China (1) · Colombia (1) · France (1) · Hong Kong (1) · Hungary (1) · India (1) · Italy (1) · Malaysia (1) · Mexico (1)